作者
Sara Y Tartof, Jeff M Slezak, Laura Puzniak, Vennis Hong, Timothy B Frankland, Bradley K Ackerson, Harpreet S Takhar, Oluwaseye A Ogun, Sarah R Simmons, Joann M Zamparo, Sharon Gray, Srinivas R Valluri, Kaije Pan, Luis Jodar, John M McLaughlin
发表日期
2022/5/1
期刊
The Lancet Regional Health–Americas
卷号
9
出版商
Elsevier
简介
Background
Globally, recommendations are expanding for third (booster) doses of BNT162b2 (Pfizer–BioNTech). In the United States, as of November 19, 2021, boosters were recommended for all adults aged 18 years and older. We evaluated the effectiveness of a third dose of BNT162b2 among adults in a large US integrated health system.
Methods
In this retrospective cohort study, we analyzed electronic health records from Kaiser Permanente Southern California between Dec 14, 2020 and Dec 5, 2021 to assess vaccine effectiveness (VE) of two and three doses of BNT162b2 against SARS-CoV-2 infections (without hospital admission) andCOVID-19-related hospital admission. VE was calculated using hazards ratios from adjusted Cox models.
Findings
After only two doses, VE against infection declined from 85% (95% CI 83–86) during the first month to 49% (46–51) ≥ 7 months following vaccination. Overall …
学术搜索中的文章
SY Tartof, JM Slezak, L Puzniak, V Hong, TB Frankland… - The Lancet Regional Health–Americas, 2022
